Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 1, 1997, Pages 28-38

  Nicolaes, G A F ^a   Thomassen, M C L G D ^a   Tans, G ^a   Rosing, J ^a   Hemker, H C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

APC resistance; factor V(Leiden); thrombin generation; thrombosis

Indexed keywords

ACTIVATED PROTEIN C; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; PLASMA; PRIORITY JOURNAL; THROMBOSIS;

EID: 0030900138     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199701000-00006     Document Type: Article

References (42)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
2. Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
3. Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrin 1995; 5: 51-57.
4. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-1993.
5. Cadroy Y, Sie P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Blood 1994; 83: 2008-2009.
6. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522.
7. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
8. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536.
9. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-1362.
10. Alhenc-Gelas M, Gandrille S, Aubry M-L, Emmerich J, Fiessinger J-N, Aiach M. Unexplained thrombosis and factor V Leiden mutation. Lancet 1994; 344: 555-556.
11. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-2524.
12. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.
13. Kalafatis M, Bertina RM, Rand MR, Mann KG. Characterixation of the molecular detect in factor VR506Q. J Biol Chem 1995; 270: 4053-4057.
14. Nicolaes GAF, Tans G, Thomassen MCLGD, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166.
15. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-614.
16. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. AmJ Obstet Gynecol 1995; 173: 210-213.
17. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-1538.
18. Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg506- > Gln mutation. Blood Coag Fibrinol 1995; 6: 245-248.
19. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Hacmost 1986; 56: 9-17.
20. Kessels H, Willems G, Hemker HC. Analysis of thrombin generation in plasma. Comp Biol Med 1994; 24: 277-288.
21. Duchemin J, Pittet J-L, Tartary M, et al. A new method based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma. Thromb Haemostas 1994; 71: 331-338.
22. Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for determination of the thrombin potential. Thromb Haemost 1993; 70: 617-624.
23. Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-138.
24. Rosing J, Bakker HM Thomassen MCLGD, Hemker HC, Tans G. Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268: 21130-21136.
25. Böttcher CJF, van Gent CM, Pries C. A rapid and sensitive sub-micro phosphorus determination. Anal Chim Acta 1961; 24: 203-207.
26. Sala N, Owen WG, Collen D. A functional assay of protein C in human plasma. Blood 1984; 63: 671-675.
27. Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-283.
28. Beauchamp NJ, Daly ME, Cooper PC, Preston FE, Peake IR. Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet 1994; 344: 694-695.
29. 2-macroglobulin with proteinases. Biochem J 1973; 133: 709-715.
30. 2-macroglobulin in some kinetic parameters of trypsin. Biochim Biophys Acta 1975; 377: 150-165.
31. 2-macroglobulin in thrombin inactivation. Thromb Haemost 1981; 45: 51-54.
32. Ronde de H, Bertina RM. Laboratory diagnosis of APC resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haem 1994; 72: 880-886.
33. Engel H, Zwang I, van Vliet HHDM, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996; 75: 267-269.
34. Henkens CMA, Bom VJJ, Seinen AJ, Meer van der J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haem 1995; 73: 402-404.
35. Bokarewa MI, Blomback M, Egberg N, Rosen S. A new variant of interaction between phospholipid antibodies and the protein C system. Blood Coag Fibrinol 1994; 5: 37-41.
36. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995; 85: 1704-1711.
37. Rotteveel RC, Roozendaal KJ, Weijers RNM, Eijsman L. Influence of heparin, protamine and polybrene on the time integral of thrombin generation (endogenous thrombin potential). Haemostasis 1996; 26: 1-10.
38. Laudano AP, Doolittle RF. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 1978; 75: 3085-3089
39. Kessels H, Béguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood - the effect of heparin and aspirin, Thromb Haemost 1994; 72: 78-83.
40. Bendetowiez AV, Kai H, Knebel R, et al. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma - a study in human volunteers. Thromb Haemost 1994; 72: 705-712.
41. Kumar R, Béguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation - evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-721.
42. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Eftect of different progestagens in low oestrogen oral contraceptives on venous thromboemboli. Lancet 1995; 346: 1582-1588.